The Deficit Reduction Act of 2005, signed into law by President Bush on Feb. 8, 2006, will overhaul the current AMP and BP process and will put an enormous strain on already exhausted infrastructures to generate monthly AMP data. CBI is proud to announce the only Summit focused exclusively on the Deficit Reduction Act. This one day event provides critical intelligence and strategy for pharmaceutical manufacturers.
The DRA’s pricing transparency provision requires that CMS post the AMP of drug products on its Web site beginning July 1st of this year and to update the data quarterly. The availability of this formerly confidential pricing statistic will change the dynamics of the marketplace for brands with therapeutic alternatives or generic competition. It will make it even more challenging for multiple source drugs to sustain their price. The DRA also mandates that manufacturers report their AMP calculations to CMS on a monthly versus a quarterly basis. It is paramount that pharmaceutical and biotech companies devise a strategy for DRA implementation now, as the stakes are high. Don’t miss this opportunity to convene with your industry counterparts and with DRA experts!